AbbVie recently inked a licensing agreement with IGI Therapeutics and its subsidiary Ichnos Glenmark Innovation for a trispecific antibody, ISB-2001, targeting multiple myeloma and potentially autoimmune diseases. The upfront payment is $700 million, with the deal potentially reaching over $1.9 billion including milestones and royalties. ISB-2001 acts on three targets—CD3 on T cells and BCMA and CD38 on tumor cells—aiming to enhance therapeutic efficacy beyond bispecific antibodies. The antibody is currently in Phase 1 trials and has received FDA Orphan Drug and Fast Track designations. Early data presented at ASCO showed a 79% overall response rate and a favorable safety profile in relapsed or refractory patients. The deal extends across North America, Europe, Japan, and China, while Glenmark retains commercial rights in emerging markets. This acquisition reflects AbbVie’s strategy to strengthen its oncology portfolio with innovative multispecific biologics.